Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis - Takeaways - MDSpire

Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis

  • By

  • Zechang Xin

  • Xiaoyu Zhu

  • Hui Qu

  • Xing Ai

  • Kaixuan Wang

  • Xinyue Li

  • Ming Wang

  • Pisong Li

  • Zhongbin Han

  • Ningxin Qu

  • Weiting Yu

  • Hongshen Chen

  • June 10, 2026

  • 0 min

Share

  • 1

    Dyslipidemia prevalence in newly diagnosed breast cancer patients is 54.1%, varying significantly by molecular subtype.

  • 2

    Intravascular tumor thrombus is consistently associated with dyslipidemia across all breast cancer subtypes.

  • 3

    Luminal A subtype shows the highest dyslipidemia prevalence, while Luminal B (HER2 negative) has the lowest.

  • 4

    Lymph node metastasis correlates with dyslipidemia specifically in Luminal B subtypes.

  • 5

    Early lipid screening and cardiovascular risk assessment are recommended to enhance cardio-oncology care.

Original Source(s)

Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis

  • by Zechang Xin, Xiaoyu Zhu, Hui Qu, Xing Ai, Kaixuan Wang, Xinyue Li, Ming Wang, Pisong Li, Zhongbin Han, Ningxin Qu, Weiting Yu, Hongshen Chen

  • June 10, 2026

Related Content

ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report

POC1A promotes malignant phenotypes in non-triple-negative breast cancer cell models with EMT- and Wnt/β-catenin-related alterations

Plasma cytokine profiles in breast cancer patients and their association with therapeutic response in Peru: a prospective cohort study